Hansoh Pharma: Aumolertinib's resubmitted EU marketing application accepted by EMA

Hansoh Pharmaceutical announced that on September 29, 2026, the group resubmitted a marketing authorization application to the European Medicines Agency for its innovative drug almonertinib in the European Union, and on October 7, 2026, received confirmation of acceptance from the EMA and officially initiated the centralized review procedure. The application covers indications for first-line treatment of adult patients with advanced non-small cell lung cancer harboring EGFR exon 19 deletion or exon 21 substitution mutations, as well as treatment of adult patients with advanced non-small cell lung cancer positive for the EGFR T790M mutation.